Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis - Summary - MDSpire

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis

  • By

  • Derrick Robertson

  • Enrique Alvarez

  • Lawrence Steinman

  • Hans-Peter Hartung

  • Peiqing Qian

  • Krzysztof Selmaj

  • Sibyl Wray

  • Daniel Wynn

  • Edward J. Fox

  • Koby Mok

  • Hari P. Miskin

  • Yihuan Xu

  • Christopher A. Garner

  • Bruce A. C. Cree

  • May 29, 2026

  • 0 min

Share

Objective:

To evaluate the efficacy of ublituximab versus teriflunomide in treatment-naïve participants and in those with symptom onset ≤ three years.

Key Findings:
  • Include participant numbers for each finding for better context.
Interpretation:

Remove unsupported conclusions and rephrase to reflect findings.

Limitations:
  • Add any limitations mentioned in the source material.
Conclusion:

Ublituximab was associated with significant treatment benefits at Week 96 in treatment-naïve participants and those receiving treatment within three years of symptom onset.

Original Source(s)

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis

  • by Derrick Robertson, Enrique Alvarez, Lawrence Steinman, Hans-Peter Hartung, Peiqing Qian, Krzysztof Selmaj, Sibyl Wray, Daniel Wynn, Edward J. Fox, Koby Mok, Hari P. Miskin, Yihuan Xu, Christopher A. Garner, Bruce A. C. Cree

  • May 29, 2026

Related Content

Long-Term Outcomes of Ublituximab Treatment in Multiple Sclerosis: Findings from the ULTIMATE I and II Open-Label Extension Trials

Physical disability, cognition, and depression as determinants of quality of life in multiple sclerosis: a cross-sectional study

The immune-endothelial axis in neurovascular pathophysiology: a framework for targeted interventions